Patents by Inventor Christopher Veldkamp

Christopher Veldkamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating inflammation with monomeric CXCL12 peptide
    Patent number: 11369662
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: June 28, 2022
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • MONOMERIC CXCL121 PEPTIDE AND USE THEREOF
    Publication number: 20200353045
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Application
    Filed: January 17, 2020
    Publication date: November 12, 2020
    Applicant: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Monomeric CXCL121 peptide and methods of treating autoimmune diseases
    Patent number: 10537613
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 21, 2020
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • MONOMERIC CXCL121 PEPTIDE AND USE THEREOF
    Publication number: 20180148490
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 31, 2018
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Monomeric CXCL12peptide and methods of use thereof
    Patent number: 9908923
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 6, 2018
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • MONOMERIC CXCL121 PEPTIDE AND METHODS OF SYNTHESIS AND USE THEREOF
    Publication number: 20150361152
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson